Loading...
Loading...
IMCR| Name | Value |
|---|---|
| Revenues | 48.1M |
| Cost of Revenue | 0.1M |
| Gross Profit | 48.0M |
| Operating Expense | 70.3M |
| Operating I/L | -22.3M |
| Other Income/Expense | -0.7M |
| Interest Income | 2.4M |
| Pretax | -23.1M |
| Income Tax Expense | 2.1M |
| Net Income/Loss | -25.2M |
Immunocore Holdings plc is a commercial-stage biotechnology company specializing in the development of immunotherapies for cancer, infectious, and autoimmune diseases. The company's flagship product, KIMMTRAK, targets unresectable or metastatic uveal melanoma. Additionally, Immunocore has ongoing programs for oncology, including IMC-C103C and IMC-F106C, both in Phase I/II trials for various solid tumor cancers. The company also focuses on infectious diseases with product candidates such as IMC-I109V for chronic hepatitis B virus and IMC-M113V in pre-clinical development for human immunosuppression virus. Furthermore, Immunocore is developing precision targeted immunosuppression for autoimmune diseases.
